Cytokinetics(US:CYTK) Prnewswire·2025-11-14 15:16Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to investor losses [1][3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Cytokinetics, with a lead plaintiff deadline set for November 17, 2025 [1][6]. Group 2: Misleading Statements - Defendants allegedly made materially false statements about the expected timeline for the NDA submission and approval process for aficamten, claiming FDA approval was anticipated in the second half of 2025 [3]. - The company failed to disclose significant risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [3][4]. Group 3: Impact on Investors - Following the revelation of the misleading information, class members who purchased Cytokinetics' common stock at inflated prices experienced substantial financial losses [5]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Cytokinetics' conduct [6].